Regulatory and capital-market developments converged with today’s focus on Alzheimer’s agitation. Alongside Auvelity’s FDA approval, the market digest included multiple financing and deal headlines that can alter biotech funding availability. The broader theme from today’s package is capital redeployment around late-stage commercial opportunities and pipeline reshaping, including company-level transactions and public market liquidity events. For biotech professionals, these items matter less for immediate clinical readouts and more for how they influence near-term runway, investor appetite, and sponsor prioritization across neurological and high-cost therapy segments. The combination of FDA-driven label expansion and financing activity reinforces that timing between regulatory milestones and market access remains a major driver of corporate decisions.